Counterproposal to Swiss cost-cutting initiative

12 May 2025

A sustainable healthcare system requires holistic approaches. However, the counterproposal to the cost-control initiative, which was rejected by the people, demonstrates once again that the Swiss healthcare system is still characterized by silo thinking: Although Parliament deliberately removed separate cost targets for each cost block from the proposal, the Federal Department of Home Affairs (FDH) and Federal Office of Public Health (FOPH) blatantly disregarded this decision and reinstated the silo mentality, according to a posting on the website of Interpharma, the association of the research-based pharmaceutical industry in Switzerland.

The equally important quality targets, on the other hand, are treated stepmotherly. There are also major question marks regarding the responsible committees. Interpharma therefore rejects the amendment to the ordinance in its current form and calls on the federal government to think in overarching approaches instead of in individual silos. This is the only way to achieve the necessary reforms in the Swiss healthcare system.

Proposed amendment rejected

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical